Connect Biopharma is a global, clinical-stage biopharmaceutical company founded by a team with broad knowledge of the drug discovery industry and expertise in targeting immunological pathways.
At Connect Biopharma, we are applying our expertise in T cell biology and our deep knowledge of the drug discovery industry to develop innovative therapies that treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. Headquartered in San Diego, California with operations in the United States and China and ongoing global clinical trials, Connect Biopharma is advancing a rich pipeline of proprietary small molecules and antibodies targeting several aspects of T cell biology associated with inflammatory diseases.
The Company’s lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, icanbelimod, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD.
The exciting and diverse product development pipeline that we have established since the company was founded in 2012 evidences the power of our expertise and technology platform.